Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics, Inc. is trading at $43.92, down 0.27% on the session. The 50 day average sits at $40.04 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 57.2, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $38.36 with resistance near $45.75, so that band frames the current range. Average daily movement is roughly $2.35, or about 5.3% of the share price, which is what any stop placement has to allow for. The overall health score of 70 out of 100 combines a trend score of 75, momentum of 88 and a risk score of 36.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.